Atrion's declining ROCE and constant capital employed suggest it may be past its growth phase. Lower returns from the same capital are not signs of a compounding machine, suggesting the market may not favor these trends.
Atrion's diminishing ROCE trend indicates it might be a mature business faced with new competition or shrinking margins, resulting in lower returns despite viable areas for capital usage. A continuation of this pattern could hinder high earnings for Atrion.
Hi there, I saw this stock ATRI down quite a bit lately but their balance sheet looks pretty solid and their revenues and profits seem to be holding up. The company sells medical products for fluid delivery, cardiovascular and ophthalmology markets. Does anyone own or have this stock on their watchlist and know much about the company and why the price is falling so rapidly?$Atrion(ATRI.US)$
Atrion股票討論區
2023Q1營收下滑15.2%,營業利潤大幅下滑56.4%,淨利潤下滑59%。
目前市盈率29.6,市盈率TTM上升到了34.4,缺乏吸引力。
暫無評論